Scientific augmentation of BPH and its treatment in Unani medicine the review
Abstract
Background: Benign Prostatic Hyperplasia (BPH), or enlargement of the prostate gland, is a prevalent condition among aging males, especially those over 50. It presents with lower urinary tract symptoms (LUTS) that impact the quality of life. In Unani medicine, BPH correlates with conditions such as Izam Gudda-e-Mazi and is interpreted through the lens of humoral imbalance, particularly thick phlegm (Balgham Ghaliz) obstructing urinary pathways. Modern and Unani systems both recognize the progressive nature of BPH and its potential complications, such as acute urinary retention and infections. Methods: This review integrates modern scientific findings on the pathophysiology, epidemiology, and treatment of BPH with Unani perspectives. It draws on current biomedical data—highlighting hormonal factors (like DHT and estrogen), metabolic syndrome, and inflammation—and compares them to Unani etiologies rooted in humoral imbalance and organ inflammation. Management strategies from both systems are explored, including allopathic pharmacotherapy (e.g., alpha-blockers, 5α-reductase inhibitors), and Unani therapies such as Ilaj-Bil-Dawa (herbal remedies), Ilaj-Bil-Tadbeer (regimental therapy), and Ilaj-Bil-Ghiza (dietary measures). Results: Modern medicine provides pharmacological and surgical solutions for BPH, albeit with potential side effects such as erectile dysfunction and reduced libido. Meanwhile, Unani treatment emphasizes natural, multi-herbal preparations that possess anti-inflammatory, diuretic, and 5α-reductase inhibitory properties. Herbal combinations—such as those including Nepeta ruderalis, Zingiber officinale, and Foeniculum vulgare—are traditionally used to alleviate symptoms like dysuria and urinary retention. Complementary medicine's rising global popularity reflects a growing preference for safer, natural alternatives. Conclusion: The convergence of Unani and modern perspectives on BPH enhances our holistic understanding of the condition and expands the therapeutic options. Herbal formulations grounded in Unani medicine offer promising, less invasive alternatives with minimal side effects. Continued scientific validation of traditional remedies could significantly benefit BPH management by reducing reliance on surgical and synthetic pharmaceutical interventions.
Keywords: Prostate gland, Prostate enlargement, LUTS, BPH, Unani, Greco-Arab medicine
Keywords:
Prostate gland, Prostate enlargement, LUTS, BPH, Unani, Greco-Arab medicineDOI
https://doi.org/10.22270/jddt.v15i5.7125References
1. Bhat SA, Rather SA, Islam N. An overview of benign prostatic hyperplasia and its appreciation in Greco-Arab (Unani) system of medicine. Asian Journal of Urology. 2022 Apr 1;9(2):109-18. https://doi.org/10.1016/j.ajur.2021.05.008 PMid:35509487 PMCid:PMC9051355
2. Shakil M, Khan MS. Benign Prostatic Hyperplasia (BPH) and its Unani management: A case report. World J Pharm Med Res. 2023;9(11):236-241.
3. Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Neal Jr DE, Terris MK, Klaassen Z. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Translational andrology and urology. 2019 Oct;8(5):529. https://doi.org/10.21037/tau.2019.10.01 PMid:31807429 PMCid:PMC6842780
4. Briganti A, Capitanio U, Suardi N, Gallina A, Salonia A, Bianchi M, Tutolo M, Di Girolamo V, Guazzoni G, Rigatti P, Montorsi F. Benign prostatic hyperplasia and its aetiologies. European Urology Supplements. 2009 Dec 1;8(13):865-71. https://doi.org/10.1016/j.eursup.2009.11.002
5. Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P, editors. Textbook of benign prostatic hyperplasia. CRC Press; 2004 Nov 29. https://doi.org/10.1201/b14479
6. Rauf E. MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA BY UNANI DRUG
7. Javed SN, Khan A. Assessment of Temperament of outdoor patients of DUMC: an observational study, ETIR;2023, 10(7):e45-e51
8. Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia-what do we know?. BJU international. 2021 Apr;127(4):389-99. https://doi.org/10.1111/bju.15229 PMid:32893964
9. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. The Prostate. 1989;15(S2):33-50. https://doi.org/10.1002/pros.2990150506 PMid:2482772
10. Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology. 2019 Aug 21;65(5):458-64. https://doi.org/10.1159/000496289 PMid:30943489
11. Boyle P, McGinn R, Maisonneuve P, La Vecchia C. Epidemiology of benign prostatic hyperplasia: present knowledge and studies needed. European urology. 1991 Jan 1;20(Suppl. 1):3-10. https://doi.org/10.1159/000471738 PMid:1722158
12. Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Neal Jr DE, Terris MK, Klaassen Z. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Translational andrology and urology. 2019 Oct;8(5):529. https://doi.org/10.21037/tau.2019.10.01 PMid:31807429 PMCid:PMC6842780
13. Quraishi HA, et al. Management of Prostatomegaly (Izam-I-Ghudda-I-Mazi) in Unani System of Medicine: An Overview. J Urol Nephrol 2019, 4(3): 000167. https://doi.org/10.23880/OAJUN-16000167
14. Edwards JL. Diagnosis and management of benign prostatic hyperplasia. Am Fam Physician. 2008 May 15;77(10):1403-10. PMID: 18533373.
15. Tanguay S, Awde M, Brock G, Casey R, Kozak J, Lee J, Nickel JC, Saad F. Diagnosis and management of benign prostatic hyperplasia in primary care. Canadian Urological Association Journal. 2009 Jun;3(3 Suppl 2):S92. https://doi.org/10.5489/cuaj.1116 PMid:19543429 PMCid:PMC2698785
16. Halawani A, Paterson R, Zhong T, Du K, Ren R, Forbes CM. Risks and side effects in the medical management of benign prostatic hyperplasia. Prostate International. 2024 Jun 1;12(2):57-64. https://doi.org/10.1016/j.prnil.2023.11.004 PMid:39036761 PMCid:PMC11255900
17. Leisegang K, Jimenez M, Durairajanayagam D, Finelli R, Majzoub A, Henkel R, Agarwal A. A systematic review of herbal medicine in the clinical treatment of benign prostatic hyperplasia. Phytomedicine Plus. 2022 Feb 1;2(1):100153. https://doi.org/10.1016/j.phyplu.2021.100153
18. Akhtar, M. S., et al. (2012). Tribulus terrestris: A review on its potential anti-inflammatory and anti-prostate cancer activities.
19. Tarique M, Ali T. EFFICACY AND SAFETY OF A UNANI FORMULATION IN THE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA.
20. Fatima T, Naseer B, Hussain SZ. Stinging Nettle: A herb with tremendous pharmacological potential. International Journal of Unani and Integrative Medicine. 2018;2(2):24-8. https://doi.org/10.33545/2616454X.2018.v2.i2a.29
21. Asare GA, Asiedu B, Naidoo V, Ablakwa J, Adjei S, Amoah B, Obeng-Kyeremeh R, Motadi L, Hossain M, Parveen M, Akter A. The impact of combination therapy of Croton membranaceus and finasteride on benign prostatic hyperplasia (BHP) histo-morphology. Phytomedicine Plus. 2024 May 1;4(2):100543. https://doi.org/10.1016/j.phyplu.2024.100543
22. MOC C. Medical management of benign prostatic hyperplasia. Cleveland Clinic journal of medicine. 2024 Mar;91(3):163. https://doi.org/10.3949/ccjm.91a.23027 PMid:38429006
23. Roehrborn CG, Siami P, Barkin J, et al. The Effects of Combination Therapy With Dutasteride and Tamsulosin on Clinical Outcomes in Men With Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study, European Urology, 2010;57(1):123-131 https://doi.org/10.1016/j.eururo.2009.09.035 PMid:19825505
Published
Abstract Display: 2064 
PDF Downloads: 758 PDF Downloads: 196 How to Cite
Issue
Section
Copyright (c) 2025 Rameez Raja Mallah, Mohammed Shakeel Ansari
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.